SCHEMBL396463

SCHEMBL396463

CNC(=O)N1c2ccc(NC)cc2Sc2cc(NC)ccc21

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ BCHE P06276 11/20 0.61
▸ ACHE P22303 1/20 0.61
▸ SNCA P37840 1/20 0.49
▸ GAA P10253 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ ALOX12 P18054 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ NOX1 Q9Y5S8 3/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1926804 0.85 NOX1 (0.54) BCHEACHESNCAKDM4EKMT2A
SCHEMBL30851251 0.85 NOX1 (0.54) BCHEACHESNCAKDM4EKMT2A
SCHEMBL12955933 0.79 MEN1 (0.63) BCHEACHESNCAHPGDKMT2A
SCHEMBL29384821 0.78 MAPK1 (0.62) BCHEACHESNCAGAAMAPT
SCHEMBL244827 0.78 MAPK1 (0.62) BCHEACHESNCAGAAMAPT
SCHEMBL8223437 0.78 NOX1 (0.46) BCHEACHESNCAKMT2ANOX1
SCHEMBL14142982 0.78 BCHE (0.61) BCHEACHESNCANOX1
SCHEMBL1828804 0.78 SNCA (0.44) BCHEACHESNCAMAPTCYP2C19
SCHEMBL18408661 0.76 MAPK1 (0.55) BCHEACHESNCAMAPTKMT2A
SCHEMBL22726491 0.75 MAPK1 (0.54) BCHEACHESNCAGAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5223404-A Chromogen, oxidase, compound which releases rate enhancer in presence of peptidase SUNSTAR KABUSHIKI KAISHA (JP) 1993-06-29 — — US claimed
US-12264356-B2 Method for determining sensitivity to SGLT2 inhibitor and sensitivity marker for SGLT2 inhibitor NIHON UNIVERSITY (JP) 2025-04-01 — — US disclosed
EP-3461907-B1 MEASUREMENT OF GLYCOPROTEIN ARKRAY INC (JP) 2023-06-14 — — EP disclosed
US-10989714-B2 Measurement of glycoprotein ARKRAY, INC. (JP) 2021-04-27 — — US disclosed
US-20200347458-A1 METHOD FOR DETERMINING SENSITIVITY TO SGLT2 INHIBITOR AND SENSITIVITY MARKER FOR SGLT2 INHIBITOR NIHON UNIVERSITY (JP) 2020-11-05 — — US disclosed
US-20190137502-A1 Measurement of Glycoprotein ARKRAY, INC. (JP) 2019-05-09 — — US disclosed
EP-3461907-A1 MEASUREMENT OF GLYCOPROTEIN ARKRAY, Inc. (JP) 2019-04-03 — — EP disclosed
EP-2319937-B1 BLOOD COMPONENT MEASUREMENT METHOD UTILIZING HEMOLYZED WHOLE BLOOD, AND KIT FOR THE METHOD NIPPON KAYAKU KK (JP) 2016-01-27 — — EP disclosed
US-8883439-B2 Blood component measurement method utilizing hemolyzed whole blood, and kit for the method NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2014-11-11 — — US disclosed
US-8753832-B2 Method of assaying 1,5 anhydroglucitol by using whole blood and measurement kit NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2014-06-17 — — US disclosed
EP-0533183-B1 Composition for the measurement of potassium ion concentration TOYO BOSEKI (JP) 1997-12-29 — — EP disclosed
US-5426033-A Accurate quantitative analysis KYOWA MEDEX CO., LTD. (JP) 1995-06-20 — — US disclosed
EP-0608795-A1 Method for enzymatic determination of substrate after enzymatically removing galactose Kyowa Medex Co. Ltd. (JP) 1994-08-03 — — EP disclosed
US-5334507-A Pyruvate kinase, glycerol kinase, glycerol-3-phosphate oxidase, peroxidase, reduced chromogen, adenosine diphosphate, phosphoenolpyruvic acid TOYO BOSEKI KABUSHIKI KAISHA (JP) 1994-08-02 — — US disclosed
EP-0533183-A2 Composition for the measurement of potassium ion concentration TOYO BOSEKI KABUSHIKI KAISHA Trading under the name of Toyobo Co., Ltd. (JP) 1993-03-24 — — EP disclosed
EP-0174371-B1 TRIPHENYLMETHANE DERIVATIVES AND METHOD FOR DETERMINING OXIDATIVE SUBSTANCES USING THEM AS COLOR-FORMING COMPONENT WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 1990-09-19 — — EP disclosed
US-4778753-A IN PRESCENCE OF URICASE, METAL CHELATE AND ANIONIC SURFACTANT; WITHOUT COLORING INTERFERENCE WAKO PURE CHEMICAL INDUSTRIES LTD. (JP) 1988-10-18 — — US disclosed
US-4673635-A Triphenyl methane derivatives and method of quantitatively measuring an oxidative substance WAKO PURE CHEMICAL INDUSTRIES LTD. (JP) 1987-06-16 — — US disclosed
US-4613465-A HYDROGEN PEROXIDE, BODY FLUIDS, ENZYMES WAKO PURE CHEMICAL INDUSTRIES LTD. (JP) 1986-09-23 — — US disclosed
EP-0174371-A1 TRIPHENYLMETHANE DERIVATIVES AND METHOD FOR DETERMINING OXIDATIVE SUBSTANCES USING THEM AS COLOR-FORMING COMPONENT WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 1986-03-19 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10989714-B2 Measurement of glycoprotein ENGASE, UGGT1, ST6GAL1 BCHE 703/4885ACHE 1316/4885SNCA 4606/4885
US-20190137502-A1 Measurement of Glycoprotein ENGASE, UGGT1, ST6GAL1 BCHE 703/4885ACHE 1316/4885SNCA 4606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback